Neurodegeneration

InvestmentPitch Media Video Discusses FSD Pharma’s Receipt of No Objection Letter from Health Canada for Clinical Trials for LUCID-21-302 for MS

Retrieved on: 
Thursday, February 9, 2023
Prevalence, NOL, Disease, MS, Safety, Pharmacy, Neurodegeneration, IR, Inflammation, Health Canada, New chemical entity, Bureau of Oceans and International Environmental and Scientific Affairs, Therapy, PEA, Degenerative disease, BioCompute Object, FSD, Central nervous system, Multiple sclerosis, Letter, Drug development, Clinical trial, CSE, Nerve, Research, News, Pharmaceutical industry

The Letter of No Objection covers the company’s proposed Phase 1 clinical trial of LUCID-21-302 or Lucid-MS, a novel drug candidate for the treatment of Multiple Sclerosis and provides FSD Pharma with regulatory approval to move forward with the clinical trial in Canada.

Key Points: 
  • The Letter of No Objection covers the company’s proposed Phase 1 clinical trial of LUCID-21-302 or Lucid-MS, a novel drug candidate for the treatment of Multiple Sclerosis and provides FSD Pharma with regulatory approval to move forward with the clinical trial in Canada.
  • A Media Snippet accompanying this announcement is available by clicking on the image or link below:
    For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company.
  • The video is available for viewing on “ InvestmentPitch ” and on “ YouTube ”.
  • If these links are not enabled, please visit www.InvestmentPitch.com and enter “FSD Pharma” in the search box.

Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease

Retrieved on: 
Thursday, February 9, 2023
Even and odd functions, Neurodegeneration, Communication, Cognition, Neuron, Literature, Synapse, Therapy, Jort, Quantitative electroencephalography, Patient, Alzheimer's disease, The New England Journal of Medicine, Eisai, Neurotoxicity, Toxicity, Brain, Research, Amyloid, Medical imaging, SEQUEL

NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that enrollment has completed in the randomized, double-blind Phase 2 SEQUEL study (COG0202, NCT04735536 ) of CT1812 in 16 adults with mild-to-moderate Alzheimer’s disease.

Key Points: 
  • NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that enrollment has completed in the randomized, double-blind Phase 2 SEQUEL study (COG0202, NCT04735536 ) of CT1812 in 16 adults with mild-to-moderate Alzheimer’s disease.
  • Topline results from SEQUEL are expected mid-2023.
  • There is substantial evidence that Aβ oligomers have the potential to impair synaptic and neuronal activity.
  • “In the SEQUEL study, we use qEEG as an experimental outcome measure to determine the effect of CT1812 on Alzheimer disease processes in the brain.

IntelGenx Announces Research Collaboration with Renowned Neurologist to Evaluate Montelukast VersaFilm® for the Treatment of Parkinson’s Disease

Retrieved on: 
Thursday, February 9, 2023
Disease, Movement disorders, Neurodegeneration, Parkinson, Cysteinyl leukotriene receptor 1, Karolinska Institute, Immunomodulation, Trial of the century, Principal, Clinical neuroscience, Per Svenningsson, TSX, Swedish Research Council, Government budget balance, Parkinson's disease, Intellectual property, Lewy body, Clinical trial, Alzheimer's disease, Leukotriene, SCI, Research, Doctor of Philosophy, Pharmaceutical industry, MD, PD, Study

$2 million USD) awarded by the Swedish Research Council, Sweden’s largest governmental research funding body.

Key Points: 
  • $2 million USD) awarded by the Swedish Research Council, Sweden’s largest governmental research funding body.
  • IntelGenx will supply Dr. Svenningsson with both active and placebo films to be used in the 18-month treatment regimen for study participants.
  • Upon completion of the Study, IntelGenx will retain the intellectual property rights and use the findings to further develop its Montelukast VersaFilm® program for Parkinson's disease treatment.
  • 2 Wallin, J; Svenningsson, P. Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease.

NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders

Retrieved on: 
Thursday, February 9, 2023
Neurodegeneration, WEHI, Medicine, Mitochondrial permeability transition pore, Degenerative disease, IND, R, Neuroinflammation, MOA, CSO, Survival, Therapy, Drug development, NRG, Drug discovery, Mitochondrion, MND, Sclerosis (medicine), ALS, MPTP, SBC, École Polytechnique, Cell, AstraZeneca, Pharmaceutical industry, Fine chemical, Galderma, Chemistry, Evotec

Dr Ouvry brings 20 years of international medicinal chemistry experience gained at Evotec, Galderma, AstraZeneca and SCYNEXIS.

Key Points: 
  • Dr Ouvry brings 20 years of international medicinal chemistry experience gained at Evotec, Galderma, AstraZeneca and SCYNEXIS.
  • NRG Therapeutics’ co-founder and CEO Dr Neil Miller said, “We are expanding following our £16m series A financing and I am delighted to welcome Gilles to our team.
  • There is now a substantial body of evidence demonstrating mitochondrial failure or dysfunction is common across many degenerative diseases.
  • Gilles Ouvry Ph.D., VP of Chemistry at NRG Therapeutics said, “I have been impressed by the potential of NRG’s small molecules and am excited to be working with the team to move the programs forward.

CENTOGENE Regains Compliance With Nasdaq Listing Requirements

Retrieved on: 
Tuesday, February 7, 2023
Neurodegeneration, Qualification, Auction

and ROSTOCK, Germany and BERLIN, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has received a notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department informing the Company that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1).

Key Points: 
  • and ROSTOCK, Germany and BERLIN, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has received a notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department informing the Company that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1).
  • As a result, CENTOGENE is now compliant with all applicable Nasdaq listing standards, and Nasdaq considers this matter closed.
  • CENTOGENE was previously notified by Nasdaq on December 12, 2022, that it was not in compliance with the minimum bid price rule, because its common stock failed to meet the closing bid price of US$1.00 or more for 30 consecutive business days.
  • To regain compliance with the minimum bid price rule, the Company was required to maintain a minimum closing bid price of US$1.00 for at least 10 consecutive business days.

CENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease Day

Retrieved on: 
Tuesday, February 7, 2023
Disease, Diagnosis, RDD, Convention, Neurodegeneration, Physician, Patient, Kiosk, Pharmaceutical industry, Customer service, Online shopping, Pharma

Since 2008, RDD has been held annually on the last day of February and includes a range of activities and initiatives throughout the month.

Key Points: 
  • Since 2008, RDD has been held annually on the last day of February and includes a range of activities and initiatives throughout the month.
  • Bringing together physicians, patient organizations, researchers, medical companies, and of course, rare disease patients from around the world, RDD raises awareness and generates change for the rare disease community.
  • CENTOGENE is committed to raising awareness and bringing support to the more than 350 million rare disease patients globally.
  • The Company invites attendees to schedule one-on-one meetings in advance to learn more about its data-driven, life-changing solutions for rare disease patients.

Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results

Retrieved on: 
Tuesday, February 7, 2023
Disease, EDGAR, Research, Clinical trial, Neurodegeneration, Rett syndrome, CNS, Cognition, Conference call, Congress, Therapy, ADAS-Cog, Webcast, Publication, Conference, Coronavirus Scientific Advisory Board (Turkey), Central nervous system, Drug development, Patient, Society, SIGMAR1, Dementia, Precision medicine, Office of the National Coordinator for Health Information Technology, Nature, Data, Doctor of Philosophy, Broadcasting, Pharmaceutical industry, Video game, MD

NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended December 31, 2022.

Key Points: 
  • Company expects to announce topline results from this study in the second half of 2023.
  • On January 12th, 2023, Anavex presented at the 41st Annual J.P. Morgan Healthcare Conference, in San Francisco, CA.
  • General and administrative expenses for the quarter of $3.3 million compared to $3.1 million for the comparable quarter of fiscal 2022.
  • Research and development expenses for the quarter of $12.1 million compared to $8.7 million for the comparable quarter of fiscal 2022.

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

Retrieved on: 
Tuesday, February 7, 2023
Amyotrophic lateral sclerosis, Barrow Neurological Institute, Target, Alpha-synuclein, Disease, Research, Diagnosis, Neurodegeneration, Pathology, The Michael J. Fox Foundation, NDD, MJFF, Frontotemporal lobar degeneration, Precision medicine, International Center, PET, FTLD, Patient, Drug discovery, ALS, Kansas City University, National Center for Research Resources, Senior, AC, TAR, Engineering, Pharmaceutical industry, Medical imaging, Biotechnology

Fox Foundation for Parkinson’s Research (MJFF) and Target ALS Foundation (Target ALS) supporting research programs to enable diagnosis of TDP-43 (TAR DNA-binding protein 43), recognized as an important target in multiple neurodegenerative diseases (NDDs) such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) and as a prominent co-pathology in Alzheimer’s and Parkinson’s diseases.

Key Points: 
  • Fox Foundation for Parkinson’s Research (MJFF) and Target ALS Foundation (Target ALS) supporting research programs to enable diagnosis of TDP-43 (TAR DNA-binding protein 43), recognized as an important target in multiple neurodegenerative diseases (NDDs) such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) and as a prominent co-pathology in Alzheimer’s and Parkinson’s diseases.
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “It is an honor to have the support of MJFF and Target ALS, two leading international organizations that recognize the pressing need for diagnostics to detect pathological TDP-43.
  • AC Immune and its collaborators recently demonstrated their expertise in developing cutting-edge PET imaging agents by providing the first images of alpha-synuclein.
  • The development of a TDP-43 specific biofluid-based diagnostic test has the potential to more rapidly enable confirmed early diagnosis.”
    The MJFF and Target ALS grants collectively provide more than USD 500,000 in additional non-dilutive capital to support the advancement of diagnostic programs targeting TDP-43.

Ashvattha Therapeutics Announces First Patient Enrolled in a Phase 1 Study of [18F]OP-801 for Use as Imaging Agent

Retrieved on: 
Monday, February 6, 2023
Amyotrophic lateral sclerosis, Disease, Stanford University School of Medicine, Safety, HD, Trial of the century, Neuroinflammation, Pharmacokinetics, Microglia, CT, Neurodegeneration, Patient, HDT, Clinical trial, ALS, Precision medicine, Doctor of Philosophy, Brain, Therapy, Inflammation, Medical imaging

REDWOOD CITY, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel nanomedicines called hydroxyl dendrimer therapeutics (HDT), today announced that the first patient has been enrolled in a Phase 1/2 clinical study to evaluate the safety, pharmacokinetics and biodistribution of an intravenously administered dose of [18F]OP-801 in healthy volunteers and in patients with amyotrophic lateral sclerosis (ALS) (NCT05395624). [18F]OP-801 is a hydroxyl dendrimer (HD) imaging agent that selectively targets reactive macrophages and microglia – key markers of neuroinflammation.

Key Points: 
  • [18F]OP-801 is a hydroxyl dendrimer (HD) imaging agent that selectively targets reactive macrophages and microglia – key markers of neuroinflammation.
  • “The initiation of the clinical trial evaluating [18F]OP-801 as an imaging agent is a significant step to unlocking the potential of our proprietary HD technology for treatment of neurological diseases,” said Jeffrey Cleland, Ph.D., chairman, CEO and president of Ashvattha Therapeutics.
  • “With [18F]OP-801, we will be able to estimate HDT uptake in the diseased part of the brain prior to treating patients with the HDT.
  • The study will also measure the biodistribution and clearance of the HD imaging agent in both populations and evaluate the uptake of [18F]OP-801 in regions of neuroinflammation in ALS patients using PET/computed tomography (CT) scans.

AC Immune to Present at the SVB Securities Global Biopharma Conference

Retrieved on: 
Thursday, February 2, 2023
Conference, Neurodegeneration, ABATE, Diagnosis, Patient, Safety, AC, Medical device

Lausanne, Switzerland, February 2, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in a fireside chat and one-on-one investor meetings during the SVB Securities Global Biopharma Conference, which is taking place virtually from February 14 – 16, 2023.

Key Points: 
  • Lausanne, Switzerland, February 2, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in a fireside chat and one-on-one investor meetings during the SVB Securities Global Biopharma Conference, which is taking place virtually from February 14 – 16, 2023.
  • The fireside chat will take place on February 14, 2023, at 8:40 AM ET / 2:40 PM CET.
  • A webcast of the fireside chat will be available on the Events Page of AC Immune’s website.
  • Following the fireside chat, a replay will be archived in the same location.